Bowyer L, Hall R R, Reading J, Marsh M M
Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK.
Br J Urol. 1995 Feb;75(2):188-92. doi: 10.1111/j.1464-410x.1995.tb07309.x.
To determine the incidence of bacille Calmette-Guérin (BCG) bacilli persisting in the urinary tract of patients treated previously with intravesical BCG for carcinoma in situ or multiple Ta.T1 transitional cell carcinoma.
One-hundred and twenty-five patients were treated at the Freeman Hospital, Newcastle upon Tyne, UK over an 8-year period, 90 of whom submitted early morning urine samples for culture for acid-fast bacilli at varying intervals following BCG treatment. The records of all patients were reviewed to determine the incidence of caseating granulomata containing acid-fast bacilli together with the incidence of toxicity and the outcome of treatment.
Five patients were found to have persisting acid-fast mycobacteria in their urine or bladder up to 16.5 months after completing intravesical instillations of BCG. In one patient this probably accounted for bladder symptoms that required palliative cystectomy. In four patients the 'infection' was not severe. Two patients were treated with antituberculous chemotherapy without complication. Three years after intravesical BCG therapy 36 of 69 patients (52%) had remained tumour free.
BCG organisms can persist in the urinary tract for at least 16.5 months after the completion of intravesical BCG instillation therapy.
确定曾接受膀胱内卡介苗(BCG)灌注治疗原位癌或多发Ta、T1期移行细胞癌的患者尿路中持续存在卡介苗杆菌的发生率。
在英国泰恩河畔纽卡斯尔的弗里曼医院,8年间共治疗了125例患者,其中90例在卡介苗治疗后的不同时间间隔提交了晨尿样本进行抗酸杆菌培养。对所有患者的记录进行了回顾,以确定含有抗酸杆菌的干酪样肉芽肿的发生率、毒性发生率及治疗结果。
5例患者在完成膀胱内卡介苗灌注后长达16.5个月,尿液或膀胱中仍有持续存在的抗酸分枝杆菌。其中1例患者的膀胱症状可能与此有关,需要进行姑息性膀胱切除术。另外4例患者的“感染”并不严重。2例患者接受抗结核化疗,未出现并发症。膀胱内卡介苗治疗3年后,69例患者中有36例(52%)无肿瘤复发。
膀胱内卡介苗灌注治疗结束后,卡介苗杆菌可在尿路中持续存在至少16.5个月。